We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Global Medical Gas Analyzers Market to Reach USD 325 Million by 2025

By LabMedica International staff writers
Posted on 01 Oct 2018
The global medical gas analyzers market was valued at USD 235 million in 2017 and is expected to grow at a CAGR of 4.1% from 2018 to 2025 to reach USD 325 million by 2025, driven by an upsurge in the adoption of medical gas analyzers, stringent regulations for medical gas systems, and increase in demand for advanced medical gas analyzing systems. More...
An increase in the number of medical gas therapies due to a surge in the number of patients treated in intensive care units (ICUs), neonatal intensive care units (NICUs), and emergency departments, as well as a surge in number of hospitals & surgery centers will further support the market growth.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Based on product, the multiple gas analyzers segment is expected to grow at a CAGR of 4.5% during the forecast period. On the basis of modality type, the portable analyzers segment held more than half the share of the medical gas analyzers market in 2017 and is expected to continue dominating the market throughout the forecast period. Based on end user, the ambulatory surgery centers segment is expected to register the fastest CAGR of 5.6% during the forecast period. Geographically, the medical gas analyzers market in Asia-Pacific is expected to register the highest CAGR of 5.4% during the forecast period.

Related Links:
Research and Markets


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.